Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Top Cited Papers
- 1 August 2016
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 70 (2), 256-262
- https://doi.org/10.1016/j.eururo.2015.11.005
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trialEuropean Journal of Cancer, 2012
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice GuidelineJournal of Clinical Oncology, 2007
- Futility approaches to interim monitoring by data monitoring committeesClinical Trials, 2006
- Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive PartitioningJournal of Urology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaThe New England Journal of Medicine, 1989